Evidence from preclinical and clinical trials suggests MET activation serves as a primary oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC) and as a secondary driver of acquired resistance to targeted therapy in EGFR-mutant [3] or ALK-positive patients [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.